Oral · GLP-1 agonist
TERN-601
1 trials in this molecule. Source: ClinicalTrials.gov, as of July 1, 2026.
Trials
1
Active
0
Recruiting
0
Completed
1
Sites
17
Countries
1
Endpoints
3
Composite endpoints
0
Distinct sites and countries across this molecule's trials. A site running several of its trials counts once, matching the map.
Development
Where the program stands
Trials by phase
Phase 2
1
Trials by status
Completed
1
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Weight & body composition
3
Most-measured metrics
Top 20 metrics across this asset's endpoints
Body weight, % changeWeight
1
Body weight, absolute change (kg)Weight
1
≥5% weight-loss respondersWeight
1
Trials
Programs for this asset
Every trial for this molecule, with the same search, filters, and sort as the Trials tab.
⌘K
1 of 1
| Asset / Population | Key I/E criterion | Evidence | ||||||
|---|---|---|---|---|---|---|---|---|
| FALCONA Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of TERN-601 in Adults With Overweight or Obesity | TERN-601 Obesity / overweight | HbA1c ≤6.5% | Ph 2 | Completed | 17 | Aug 2025 | — |